Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis

Klebanoff, Matthew J.; Corey, Kathleen E.; Chhatwal, Jagpreet; Kaplan, Lee M.; Chung, Raymond T.; Hur, Chin

doi:10.1002/hep.28958

Cited by 85 publications

(71 citation statements)

References 54 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are corroborated by the Lille data from France [227]. Using a state-transition model, Klebanoff et al [357] aimed to assess the effectiveness and cost-effectiveness of surgery or intensive lifestyle intervention to manage NASH. Both interventions increased QALYs compared to no intervention.…”

Section: Commentarymentioning

confidence: 87%

ESPEN guideline on clinical nutrition in liver disease

et al. 2019

View full text Add to dashboard Cite

This update of evidence-based guidelines (GL) aims to translate current evidence and expert opinion into recommendations for multidisciplinary teams responsible for the optimal nutritional and metabolic management of adult patients with liver disease. The GL was commissioned and financially supported by ESPEN. Members of the guideline group were selected by ESPEN. We searched for meta-analyses, systematic reviews and single clinical trials based on clinical questions according to the PICO format. The evidence was evaluated and used to develop clinical recommendations implementing the SIGN method. A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct from fatty liver disease. The recommendations are preceded by statements covering current knowledge of the underlying pathophysiology and pathobiochemistry as well as pertinent methods for the assessment of nutritional status and body composition.

show abstract

Section: Commentarymentioning

confidence: 87%

ESPEN guideline on clinical nutrition in liver disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Bariatric surgery not only reduces cardiovascular mortality and all‐cause mortality, but also improves histological changes of NASH. However, its role in reversing liver fibrosis and reducing liver mortality remains unclear . Currently, there is no enough evidence to recommend bariatric surgery as the routine treatment of NASH.…”

Section: Prvention and Treatmentmentioning

confidence: 99%

Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)

Fan

Wei

Zhang

2018

J of Digest Diseases

159

132

View full text Add to dashboard Cite

“…Considerable disagreement exists between different guidelines regarding screening of general population for NAFLD because 1) only a small proportion of the general population has severe liver disease because of NAFLD though it is a common cause of CLD 20 , 2) type 2 diabetes is associated with higher prevalence of NAFLD, NASH and advanced fibrosis [21][22][23] , 3) effective drug treatment is not still available, 4) lack of sensitive diagnostic tests except liver biopsy which is a risky procedure and 5) cost-effective analysis are scarce 24 .…”

Section: Screening For Nafldmentioning

confidence: 99%

Current Management Strategy of Non-Alcoholic Fatty Liver Disease

Perveen¹

2019

J Enam Med Col

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and is becoming the most common indication for liver transplant in the Western world. The disease spectrum varies from steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis and hepatocellular carcinoma. The global prevalence of NAFLD and NASH varies from 24-25% and 1.5-6.45% respectively among general population. Despite the disease burden and adverse outcome of the condition, no highly effective treatment is currently available for NAFLD. Considering its global prevalence and impact clinicians and researchers from different scientific associations worldwide tried hard to develop high-quality international guidelines to improve the management of NAFLD patients in clinical practice. This paper aims to discuss the management options for NAFLD based on five different well-known international guidelines. These guidelines agree on many points and disagree on some points. Notably these guidelines differ in determining alcohol threshold for defining NAFLD, in screening strategies in high-risk patients, the non-invasive test proposed for the diagnosis of NAFLD and advanced fibrosis in patients with NAFLD, in the follow-up protocols and, finally, in the proposed pharmacological treatment strategy.

show abstract

Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis

Cited by 85 publications

References 54 publications

ESPEN guideline on clinical nutrition in liver disease

ESPEN guideline on clinical nutrition in liver disease

Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)

Current Management Strategy of Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About